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Objective: Tumor necrosis factor- is a proinflammatory mediator required for the
development of experimental lung ischemia-reperfusion injury. The alveolar mac-
rophage is a rich source of tumor necrosis factor- in multiple models of acute lung
injury. The present study was undertaken to determine whether the alveolar mac-
rophage is an important source of tumor necrosis factor- in lung ischemia-
reperfusion injury and whether suppression of its function protects against injury.
Methods: Left lungs of Long-Evans rats underwent normothermic ischemia for 90
minutes and reperfusion for up to 4 hours. Treated animals received gadolinium
chloride, a rare earth metal that inhibits macrophage function. Injury was quantitated
via lung tissue neutrophil accumulation (myeloperoxidase content), lung vascular
permeability, and bronchoalveolar lavage fluid leukocyte, cytokine, and chemokine
content. Separate samples were generated for immunohistochemistry.
Results: Tumor necrosis factor- secretion occurred at 15 minutes of reperfusion
and was localized to the alveolar macrophage by immunohistochemistry. In gado-
linium-treated animals, lung vascular permeability was reduced by 66% at 15
minutes (P  .03) of reperfusion and by 34% at 4 hours (P  .02) of reperfusion.
Suppression of macrophage function resulted in a 35% reduction in lung myelo-
peroxidase content (P  .03) and similar reductions in bronchoalveolar lavage
leukocyte accumulation. Tumor necrosis factor- and microphage inflammatory
protein-1 protein levels were markedly reduced in the bronchoalveolar lavage of
gadolinium-treated animals by enzyme-linked immunosorbent assay.
Conclusions: The alveolar macrophage secretes tumor necrosis factor- protein by
15 minutes of reperfusion, which orchestrates the early events that eventually result
in lung ischemia-reperfusion injury at 4 hours. Gadolinium pretreatment markedly
reduces tumor necrosis factor- elaboration, resulting in significant protection
against lung ischemia-reperfusion injury.
Lung ischemia-reperfusion injury (LIRI) is a major complication oflung transplantation and pulmonary thromboendarterectomy. It isassociated with an increase in vascular permeability that is manifestpathologically as an edematous lung infiltrated by inflammatorycells.1 In previously published animal models, the vascular injuryhas been biphasic in nature.2 Although the late phase is dependent on
neutrophil recruitment and activation, the early injury is neutrophil-independent and
occurs by 15 minutes of reperfusion. As early injury occurs well before significant
tissue neutrophil infiltration has occurred, it is likely dependent on a resident cell
type such as the alveolar macrophage (AM). AM, via their ability to secrete oxygen
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and nitrogen-derived free radicals and proinflammatory cy-
tokines such as tumor necrosis factor- (TNF-), have been
shown to play a central and functional role in a variety of
acute lung injury models.3-5 In response to oxidant stress in
vitro, the AM rapidly secretes TNF-.6 TNF- is believed
to potentiate the release of chemokines and cytokines, in-
crease lung vascular permeability, and modulate the even-
tual recruitment and activation of neutrophils (effector cells
believed to mediate late reperfusion injury). These notions
have previously been published in a lung ischemia-reperfu-
sion model as there was a marked reduction of neutrophils
found in bronchoalveolar lavage fluid after anti-TNF- an-
tibody pretreatment.7,8
Gadolinium chloride is a rare earth metal that is known
to inhibit macrophage function in vivo and has been used
previously to define macrophage function in various exper-
imental models.4,5 Given that the early changes in vascular
permeability are likely dependent on a resident cell and that
the secretion of TNF- is critical to the development of
LIRI, we hypothesized that AM would be an important
source of TNF- and that their suppression with gadolinium
chloride would be protective against acute reperfusion in-
jury.
Methods
Reagents
All reagents, including gadolinium chloride, were purchased from
Sigma Chemical (St Louis, Mo) unless otherwise specified.
Animal Model
Pathogen-free Long-Evans rats (Simonsen Labs, Gilroy, Calif),
weighing 250 to 300 g, were used for all experiments. All animals
received humane care in compliance with the guidelines for care
and use of laboratory animals published by the National Society
for Medical Research and the National Institute of Health. A warm
in situ ischemia-reperfusion model was utilized as has been de-
scribed previously.9 Anesthesia was induced with pentobarbital
(35 mg/kg) and animals were ventilated by tracheostomy (Harvard
Apparatus Inc, Holliston, Mass). All animals received 0.2 mg of
atropine intramuscularly and 50 U of intravenous heparin. Anes-
thesia was maintained with inhaled halothane. The left lung was
mobilized atraumatically through an anterolateral thoracotomy and
the left pulmonary artery, veins, and bronchus were occluded with
a noncrushing microvascular clamp. At the end of the 90-minute
ischemic period, the clamp was removed and the lung was venti-
lated and reperfused for periods up to 4 hours. At the conclusion
of the reperfusion period, blood samples were obtained from the
inferior vena cava, the heart-lung block was rapidly excised, and
the pulmonary circulation was flushed with 20 mL of saline
through the main pulmonary artery.
Treated animals received 7 mg/kg of intravenous (IV) gadolin-
ium chloride 24 hours prior to injury, and control animals received
an equivalent volume of saline. A third group received 7 mg/kg IV
gadolinium 24 hours prior to the experiment and did not undergo
ischemia or reperfusion. Unmanipulated, untreated animals were
put to death for comparative purposes. All groups contained at
least 4 animals.
Lung Permeability Index
To quantitate lung vascular injury secondary to ischemia and
reperfusion, a permeability index was determined. 125I-radiola-
beled bovine serum albumin (125I-BSA; NEN Life Sciences, Bos-
ton, Mass), titrated to an activity of 800,000 counts per minute
(cpm) per dose, was intravenously injected in a final volume of 1
mL of 1% BSA/phosphate-buffered saline solution 5 minutes prior
to removal of the hilar clamp. At the end of the experiment, the
radioactivity was quantitated in the left lung as well as in 1 mL of
inferior vena cava blood using a gamma counter. The permeability
index was calculated as follows: permeability index (PI)  left
lung (cpm)/1.0 mL blood (cpm). This ratio corrects for any vari-
ation in systemic blood levels of radioactivity and provides a
reproducible measure of lung microvascular permeability.9
Myeloperoxidase Assay
Myeloperoxidase (MPO) content was used to quantitate lung tissue
neutrophil accumulation as described previously.9 Lung samples
were homogenized in a phosphate buffer containing 0.5% hexa-
decyltrimethylammonium bromide. Samples were assayed for the
ability to decompose H2O2 in the presence of O-dianisidine dihy-
drochloride by the change in absorption at 460 nm over 1 minute.
Bronchoalveolar Lavage
Additional animals underwent bronchoalveolar lavage (BAL) at
the time of sacrifice. Through the tracheostomy, lungs were la-
vaged individually by clamping the contralateral hilum and instill-
ing 3 mL of saline. This fluid was centrifuged (1500g for 8 minutes
at 4°C) to pellet the cells. The supernatant was snap frozen for
cytokine analysis after the addition of a protease inhibitor. The red
blood cells were lysed and the pellet was resuspended in saline.
Cells were counted using a hemacytometer (Hausser Scientific,
Reading, Pa).7
Enzyme-Linked Immunosorbent Assay
A sandwich enzyme-linked immunosorbent assay (ELISA) for
macrophage inflammatory protein-1 (MIP-1) has been devel-
oped in our laboratory.10 Briefly, 10 g/mL of anti-MIP-1 anti-
body (Peprotech, Rocky Hills, NJ) was coated overnight at 4°C in
a 96-well (Dynex) immunoassay plate. After blocking with 1%
BSA in saline (30 minutes at 37°C), samples and standards were
added to each well for a 1-hour incubation (37°C). Secondary
anti-MIP-1 biotinylated antibody (2 g/mL; Peprotech) was
added to each well (1-hour incubation at 37°C). After a 30-minute
incubation with a streptavidin-horseradish-peroxidase conjugate
(Pierce, Rockford, Ill), the assay was developed by adding o-
phenylenediamine dihydrochloride substrate. The reaction was
stopped by adding 50 L of 3 mol/L H2SO4. The linear sensitivity
range of the assay has been determined and the assay shows no
cross reactivity with other chemokines. TNF- ELISA was per-
formed according to manufacturer’s guidelines (R&D Systems,
Abingdon, UK). Samples and standards were run in triplicate, and
well-to-well variation did not exceed 5%.
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Immunohistology
Whole lung tissue specimens were fixed in formalin and dehy-
drated, cleared, infiltrated, and embedded in paraffin. Specimens
were cut into 5-m serial sections and baked overnight at 50°C. In
preparation for immunohistochemistry (IHC), sections were dew-
axed and rehydrated through graded alcohols to a final distilled
water wash. Following the blocking step, the primary anti-TNF-
(8 g/mL; Peprotech), anti-caspase 3 (Cell Signaling, Beverley,
Mass), or anti-macrophage (25 ucg/mL) antibody HAM-56 (DA-
KO,Carpinteria, Calif) was incubated with the samples overnight
at 4°C. Stained sections were examined using the image analysis
software, Image Pro Plus (Media Cybernetics, Silver Spring, Md).
Statistical Analysis
Descriptive statistics (mean, standard errors) were used to describe
the permeability index, MPO levels, cytokine levels, and BAL cell
counts. Continuous variables were compared between groups us-
ing Mann-Whitney rank-sum tests. Stata 7.0 software (StataCorp,
College Station, Tex) was used for the analysis.
Results
Lung Permeability Index at 15 Minutes and 4 Hours
of Reperfusion
There was a slight increase in permeability index between
unmanipulated, normal animals and animals receiving gad-
olinium pretreatment but no surgical manipulation (P 
.26). Animals undergoing 90 minutes of ischemia followed
by 15 minutes of reperfusion (IR15) demonstrated a signif-
icant rise in mean permeability index compared with unma-
nipulated gadolinium-treated animals and normal animals.
This rise was reduced in the gadolinium-treated group (IR15
GAD) at 15 minutes of reperfusion by 66% (Figure 1).
There was also a significant increase in permeability
index in control animals undergoing 90 minutes of ischemia
followed by 4 hours of reperfusion. Gadolinium pretreat-
ment caused a 34% reduction in permeability index at 4
hours of reperfusion (IR4 GAD) (Figure 1).
Myeloperoxidase Content and Bronchoalveolar Lavage
Cell Count
Lung tissue neutrophil sequestration (MPO content) in-
creased over 10-fold and BAL cell count by 26-fold in
animals subjected to 90 minutes of ischemia followed by 4
hours of reperfusion (IR4) relative to unmanipulated normal
animals. There was a 35% (Figure 2, A) reduction in MPO
and 40% reduction (Figure 2, B) in BAL cell counts in
gadolinium-treated animals at 4 hours of reperfusion (IR4
GAD) compared with untreated animals undergoing isch-
emia followed by 4 hours of reperfusion.
ELISA for MIP-1 and TNF-
To determine whether inhibition of macrophage function
was associated with a reduction in cytokine elaboration,
MIP-1 and TNF- levels were studied in the lavage fluid
of injured lungs with ELISA. These 2 mediators were se-
lected because we have previously defined their function in
the development of LIRI. MIP-1 secretion increased sig-
nificantly in animals that underwent 90 minutes of ischemia
and 4 hours of reperfusion (IR4) compared with unmanipu-
lated normal animals. Gadolinium treatment (IR4 GAD)
was associated with a nonsignificant but 50% reduction in
MIP-1 levels. Similarly, TNF- secretion increased by
24-fold in animals undergoing ischemia then 4 hours reper-
Figure 1. Lung vascular injury at 15 minutes and 4 hours of reperfusion.
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fusion (IR4) and was significantly reduced by 47% in gad-
olinium pretreated animals (IR4 GAD; Figure 3).
TNF- Immunohistochemistry
Injured lungs were analyzed by IHC for expression of
TNF-. There was minimal positive TNF- staining in
unmanipulated lungs (Figure 4, A). However, there was
detectable TNF- expression in mononuclear phagocytic
cells located in the alveoli, interstitium, and around blood
vessels after 90 minutes of ischemia only. These cells were
confirmed to be AM by immunostaining with an anti-mac-
rophage antibody (HAM 56). Following 15 minutes of
reperfusion, the staining became much more intense, espe-
cially in perivascular AM around blood vessels (Figure 4,
B). The degree of positive staining was reduced in the
gadolinium-treated group (Figure 4, C). Densitometric anal-
ysis was performed on multiple images and the results are
shown in Figure 4, D.
Caspase 3 Immunohistochemistry for Apoptosis
In sections from untreated, unmanipulated lungs there was
minimal positive caspase staining. However, in unmanipu-
lated lungs from animals treated with gadolinium 24 hours
previously, scattered mononuclear inflammatory cells
stained intensely for caspase 3. Densitometric analysis was
performed on multiple images to quantitate the degree of
apoptosis as assessed by caspase 3 staining. These results
are shown in Figure 5. These cells were identified as alve-
olar and interstitial macrophages by staining of serial sec-
tions with a specific macrophage marker (HAM 56). Rep-
resentative images stained for caspase 3 (Figure 6, A) and
HAM-56 (Figure 6, B) are shown.
Discussion
TNF- is secreted by a variety of cells including macro-
phages, monocytes, T cells, natural killer cells, and neutro-
phils. It also has an assortment of proinflammatory activities
including leukocyte chemoattraction, phagocyte stimula-
tion, vascular permeability modulation, enhancement of cy-
tokine and chemokine production, and variable effects on
cell growth and death. Functional roles for TNF- have
been identified in liver,11 heart,12 brain,13 kidney,14 hind
limb,15 and gut16 ischemia-reperfusion injury. These studies
have demonstrated that TNF- promotes injury in these
models and that its blockade limits injury via decreased
tissue neutrophil recruitment. Additionally, a role for
TNF- in remote lung injury has been shown in liver17and
intestine18 ischemia-reperfusion models.
Studies have also defined a functional role for TNF- in
acute nonischemic lung injury secondary to lipopolysaccha-
ride aspiration,19 immunoglobulin G immune-complex dep-
osition,20 and anti-glomerular basement membrane anti-
body21 models, all of which were neutrophil-dependent.
We7,22 and others8 have demonstrated a functional role for
TNF- in LIRI. It appears TNF- is released early in the
injury process and then regulates the expression of other
proinflammatory cytokines.7 These chemokines, in turn,
promote neutrophil recruitment and activation.
The alveolar macrophage has an incredible range of
biologic activities through its ability to synthesize and se-
crete an array of growth factors, cytokines, chemokines,
Figure 2. A, Lung tissue MPO content. B, Alveolar leukocyte cell
counts.
Figure 3. TNF- lavage content.
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arachidonic metabolites, and oxygen radicals. Alveolar
macrophages residing at the air–tissue interface and inter-
stitial macrophages surrounding the vasculature are the
early, rapid response immune effector cells responding to a
wide variety of toxic, infectious, and allergenic stimuli.23
Additionally, suppression of AM function has been shown
to be protective in a wide variety of models.3-5 Until re-
cently, the role of the AM in LIRI has been unclear. Prior
work suggested that inhibition of macrophage function with
gadolinium improves pulmonary hemodynamics early in
reperfusion in an isolated perfused lung model.24 However,
this was not associated with significant improvement in
objective parameters of lung injury. Furthermore, in that
study, the early improvement in injury associated with gad-
olinium treatment did not result in significant protective
effects later in reperfusion. Therefore, this suggested that
the AM may not be critical to the development of florid
reperfusion injury. This contradiction to our present find-
ings may be explained partly in that the isolated model
likely does not reflect in situ physiology. We have previ-
ously shown marked protection against LIRI using clodr-
onate-encapsulated liposomes in a warm in situ ischemia
model.22 Macrophage depletion with intratracheally deliv-
ered liposomes is effective in targeting alveolar macro-
phages predominantly as they are avidly engulfed by AM,
resulting in apoptosis shortly thereafter.25
Gadolinium is a well-recognized means of suppressing
macrophages experimentally,4,5,26 but clinically is not prac-
tical because of the requirement of 24 hours of pretreat-
ment.26 Furthermore, the precise mechanism by which it
suppresses macrophage function is still poorly understood.
The phagocytic and oxidative function of alveolar and in-
terstitial macrophages, for example, may be unaffected by
gadolinium treatment.26 However, in vitro incubation with
gadolinium has been shown to induce apoptosis in alveolar
macrophages,27 and we have shown that in vivo gadolinium
also exerts this phenomenon. The suppression of total body
macrophage function, including those in the liver and
spleen, the abnormalities induced in the clotting cascade,
and the inhibition of hepatocyte function after gadolinium
administration also limit its systemic utility.28 These limi-
tations likely have little impact on the early, direct lung
injury that is evident in this model. Gadolinium is also
commonly used as a blocker for mechanogated cation chan-
nels and in this role has been shown to prevent high airway
pressure-induced permeability changes in lungs in previous
studies.29 It may be that some of the protection observed in
the gadolinium-treated animals is due to protection against
Figure 4. A-C, Immunohistochemistry for TNF-. D, Relative den-
sitometry for TNF- immunohistochemistry.
Figure 5. Relative densitometry for caspase-3
immunohistochemistry.
Figure 6. Immunohistochemistry for caspase-3 and HAM-56.
Cardiothoracic Transplantation Naidu et al
1506 The Journal of Thoracic and Cardiovascular Surgery ● May 2004
TX
increase in permeability via modulation of stretch receptors.
Given that early and late parameters of lung reperfusion
injury are reduced with gadolinium treatment, coupled with
the significant reduction of TNF- expression, makes it
highly likely that the AM plays a central role in inciting the
events that lead to florid reperfusion injury. Targeting a
specific cell type, rather than attempting to block specific
mediators, may prove to be an effective strategy in prevent-
ing or treating LIRI. The present studies demonstrate that
oxidant-stressed AMs are an important early source of
proinflammatory mediators such as TNF-, which prime the
endothelium, epithelium, and interstitial cells and ultimately
foster the recruitment of inflammatory cells and the eventual
development of tissue injury.
Early in lung IRI, TNF- secretion is localized to the
AM. In IHC samples at 1 hour of reperfusion, there was
marked positive staining in AM, as well as endothelial cells
and type II pneumocytes. This staining of these other cell
types may be due to a paracrine phenomenon, as our pre-
vious in vitro work with both these latter cell types has not
demonstrated significant TNF- secretion subsequent to
conditions of hypoxia and reoxygenation (data not shown).
However, there has been evidence that rat type II pneumo-
cytes can produce TNF- in response to LPS stimulation.30
Therefore, further work will be required to determine the
actual response to LIRI in regards to TNF- secretion. As
TNF- has been shown directly to increase endothelial
permeability in vitro and in vivo,31,32 macrophage-derived
TNF- may mediate the early transient rise in vascular
permeability seen in this model. Therefore, macrophage-
derived TNF- likely primes, both in an autocrine and
paracrine fashion, several resident cell types to produce
chemokines, cytokines, and adhesion molecules in response
to oxidant stress. The reduction in the MIP-1 and TNF-
secretion at 4 hours of reperfusion and the concomitant
reduction in influx of neutrophils (MPO and BAL cell
count) seen with gadolinium pretreatment support this no-
tion.
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